Hormone therapy, particularly oral conjugated equine estrogen with progestin, may increase the risk of venous thromboembolism. — Whalespan
Hormone therapy, particularly oral conjugated equine estrogen with progestin, may increase the risk of venous thromboembolism.
⚠ High risk
We can't find evidence that holds up here. Proponents are reasoning from mechanism or analogy rather than direct human data, and the most credible skeptics raise objections we can't dismiss.
✕NOTSUPPORTED
⚠
High-risk intervention — consult a physician before acting.Drug-drug interactions, dose-dependence, and screening contraindications apply.
“in higher risk women particularly those that are farther out from the menopause transition or those with established cardiovascular disease these adverse changes you know may outweigh any favorable benefits and that's why probably the Women's Health Initiative who had the mean age of 63 most of these women were quite far from the menopause transition and the Women's Health Initiative also used an oral conjugated equine estrogen with progestin formulation that we saw you know an increased risk including a two-fold increased risk of venous thromboembolism”
Conflict Watch
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.